Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirellizumab Combined With TP Neoadjuvant Therapy in Early Oral Squamous Cell Carcinoma
NCT07267286Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2024
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in oral squamous cell carcinoma (OSCC), sponsored by Sun Yat-sen Memorial Hospital. Started Dec 2024; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT07267286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07267286.